Core Viewpoint - Pasithea Therapeutics Corp. has appointed Dr. James Lee to its scientific advisory board to guide the development of PAS-004, a next-generation macrocyclic MEK inhibitor, for treating ETS2 pathway inflammatory diseases such as inflammatory bowel disease (IBD) [1][3] Company Overview - Pasithea Therapeutics is a clinical-stage biotechnology company focused on developing PAS-004, which targets RASopathies, MAPK pathway-driven tumors, and other diseases [5] - The company is currently conducting a Phase 1 clinical trial of PAS-004 in advanced cancer patients and a Phase 1/1b trial in adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas [5] Dr. James Lee's Expertise - Dr. Lee is recognized for his research on the ETS2 pathway in inflammatory diseases and has published significant findings in prestigious journals like Nature [2][4] - His clinical research has the potential to lead to transformative therapies for patients with IBD, and his guidance is expected to expand PAS-004's development to additional indications beyond NF1 [3] Research and Development Focus - The company aims to fund the development of PAS-004 through non-dilutive financing, including grants and strategic collaborations [3]